Key facts
- Notable investors include Pioneer Fund, Cerity Partners Ventures, Interface Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Thornhill Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Thornhill Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Thornhill Therapeutics
Developer of an oral delivery platform designed for bio-based drugs. The company's technology enables the oral administration of traditionally injectable biologics, helping patients to improve compliance and accessibility while reducing healthcare costs for complex therapeutic proteins and peptides.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2023
- Website
- thornhill.bio/
- Ownership
- Privately Held (backing)
Thornhill Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Thornhill Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Thornhill Therapeutics in its N-PORT filings yet. We sweep new filings monthly.